This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_BONE_CARTILAGE_NAS_EXALLC for full statistics.
Malignant neoplasm of bone and articular cartilage of other and unspecified sites
C3_BONE_CARTILAGE_NAS
bone neoplasm: A benign, intermediate, or malignant neoplasm involving the bone or articular cartilage.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
164 |
4. Check minimum number of eventsNone |
164 |
5. Include endpointsNone |
164 |
6. Filter based on genotype QC (FinnGen only) |
164 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of bone and articular cartilage of other and unspecified sites
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of bone and articular cartilage
- Malignant neoplasm of bone and articular cartilage of other and unspecified sites, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of bone and articular cartilage, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 164 | 76 | 88 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | 58.01 | 55.37 | 60.28 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 155
- Matched controls
- 1548
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
133.6
38.8
40
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
21.9
32.2
48
31
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
192.0
30.9
31
*
C90.0
ICD-10 Finland
Multiple myeloma
48.2
23.6
28
7
H02AB02
ATC
dexamethasone; systemic
8.9
23.5
55
90
XW000
NOMESCO Finland
Bone marrow biopsy
17.6
22.7
36
26
L03AA02
ATC
filgrastim; parenteral
23.3
22.4
32
17
JN4BD
NOMESCO Finland
Extensive body CT
7.6
21.7
57
110
NER30
NOMESCO Finland
Extended excision of soft tissue tumour of pelvis
227.8
20.0
20
*
N02AA05
ATC
oxycodone; systemic
6.6
20.0
59
132
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
5.0
19.9
95
371
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
31.2
18.5
24
9
C90.2
ICD-10 Finland
Extramedullary plasmacytoma
189.4
16.8
17
*
XX3DW
NOMESCO Finland
Time consuming IT work
6.4
16.2
46
95
130
Kela drug reimbursment
Malignant tumour
7.7
15.9
39
65
WF049
NOMESCO Finland
Radiotherapy of metastasis
14.6
15.6
26
21
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
10.9
15.0
29
32
9220/3-C41.3
ICD-O-3
Chondrosarcoma, NOS, of rib, sternum, clavicle and associated joints
+∞
14.8
14
*
C41.49
ICD-10 Finland
Malignant tumor of the pelvic bones, sacrum and coccyx other or unspecified histology
+∞
14.8
14
*
N03AX16
ATC
pregabalin; oral
4.3
14.0
64
219
WW300
NOMESCO Finland
Transfer of autologic stem cells
54.9
13.1
15
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.5
13.0
53
161
JN4AD
NOMESCO Finland
Body CT examination
6.1
12.9
37
76
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
76.2
12.8
14
*
9370/3-C41.4
ICD-O-3
Chordoma, NOS, of pelvic bones, sacrum, coccyx and associated joints
+∞
12.7
12
*
A03FA01
ATC
metoclopramide; systemic, rectal
4.0
12.5
59
205
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
23.6
12.3
17
8
A04AA01
ATC
ondansetron; systemic, rectal
6.9
12.2
31
54
R4110
NOMESCO Finland
Physiotherapy
3.7
11.9
65
253
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
70.4
11.8
13
*
C41.32
ICD-10 Finland
Chondrosarcoma of the ribs, sternum and clavicle
+∞
11.6
11
*
C41.42
ICD-10 Finland
Chondrosarcoma of the pelvic bones, sacrum and coccyx
+∞
11.6
11
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.4
11.5
31
58
153
Kela drug reimbursment
Lenalidomid
38.1
11.5
14
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
22.1
11.4
16
8
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.3
11.2
98
532
NE1AA
NOMESCO Finland
Pelvis X-ray examination
6.4
11.2
30
56
L04AX04
ATC
lenalidomide; oral
64.5
10.8
12
*
GAE06
NOMESCO Finland
Excision of lesion of chest wall
117.6
10.6
11
*
C41.40
ICD-10 Finland
Pelvic bones, sacrum and coccyx
+∞
10.5
10
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
8.0
10.3
23
33
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
6.7
10.2
26
45
L03AA13
ATC
pegfilgrastim; parenteral
9.8
10.1
20
23
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
5.4
10.1
31
68
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
18.3
10.1
15
9
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
12.6
9.8
17
15
B01AB05
ATC
enoxaparin; parenteral
3.1
9.8
71
331
NE1DG
NOMESCO Finland
Pelvic, hip and femur very extensive MRI examination with high intensity magnet
58.7
9.8
11
*
AA1AA
NOMESCO Finland
Head X-ray examination
32.2
9.5
12
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
8.7
9.5
20
26
9731/3-C41.3
ICD-O-3
Plasmacytoma, NOS, of rib, sternum, clavicle and associated joints
+∞
9.5
9
*
9220/3-C41.4
ICD-O-3
Chondrosarcoma, NOS, of pelvic bones, sacrum, coccyx and associated joints
+∞
9.5
9
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.1
9.4
67
307
A04AA02
ATC
granisetron; systemic, transdermal
5.7
9.0
26
53
329
Kela drug reimbursment
Lenalidomide
53.0
8.8
10
*
NE1BG
NOMESCO Finland
Pelvic, hip and femur MRI examination with high intensity magnet
11.0
8.8
16
16
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.5
8.8
26
55
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
21.5
8.6
12
6
WF002
NOMESCO Finland
Radical radiotherapy
5.7
8.5
24
48
9731/3-C41.2
ICD-O-3
Plasmacytoma, NOS, of vertebral column
+∞
8.4
8
*
WW500
NOMESCO Finland
Blood transfusion
7.6
8.4
19
28
WZC30
NOMESCO Finland
Teaching
3.7
8.3
39
130
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.8
8.1
35
109
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
14.0
8.0
13
10
J05AB01
ATC
aciclovir; systemic
3.2
7.9
46
180
ZX120
NOMESCO Finland
Intravenous
4.3
7.7
29
79
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.5
7.6
22
45
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
5.4
7.5
22
46
C41.41
ICD-10 Finland
Osteosarcoma of the pelvic bones, sacrum and coccyx
+∞
7.3
7
*
NK6BN
NOMESCO Finland
Bone dynamic isotope examination
+∞
7.3
7
*
C41.3
ICD-10 Finland
Malignant neoplasm: Ribs, sternum and clavicle
+∞
7.3
7
*
9680/3-C41.4
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of pelvic bones, sacrum, coccyx and associated joints
+∞
7.3
7
*
NER20
NOMESCO Finland
Incomplete excision of soft tissue tumour of pelvis
+∞
7.3
7
*
GAE23
NOMESCO Finland
Resection of chest wall and prosthetic repair
+∞
7.3
7
*
C41.22
ICD-10 Finland
Chondrosarcoma of the spine
+∞
7.3
7
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
5.7
7.2
20
39
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
21.2
7.2
10
5
JN4CD
NOMESCO Finland
Very extensive body CT
5.6
7.1
20
40
NE1AD
NOMESCO Finland
Pelvis and hip bones CT examination
14.7
7.0
11
8
R50.9
ICD-10 Finland
Fever, unspecified
3.2
6.9
38
141
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
11.7
6.9
12
11
WX402
NOMESCO Finland
General anaesthesia
3.1
6.9
41
161
Z51.5
ICD-10 Finland
Palliative care
5.0
6.8
21
47
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.0
6.8
21
47
WF004
NOMESCO Finland
Palliative radiotherapy
10.7
6.7
12
12
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
15.1
6.5
10
7
B01AB10
ATC
tinzaparin; parenteral
4.7
6.4
21
50
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
27.9
6.3
8
*
9220/3-C41.0
ICD-O-3
Chondrosarcoma, NOS, of bones of skull and face and associated joints
+∞
6.3
6
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
7.2
6.2
14
21
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.0
6.1
37
146
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
6.3
6.0
15
26
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
55
9.92
31.75
12.7
4.1
43.8
32.2
mg/l
0.17
36
41
42
55
9.92
31.75
12.8
4.1
34.7
167.0
mg/l
0.54
36
41
67
159
6.43
29.23
8.0
4.6
226.9
251.2
u/l
1.01
67
152
64
197
4.69
19.69
6.7
7.0
1.0
1.0
mmol/l
0.01
64
183
16
16
10.97
14.25
1.2
1.6
—
—
—
0
0
65
250
3.65
13.99
5.5
4.5
0.8
0.8
mmol/l
0.14
65
236
131
811
4.06
12.72
22.7
10.7
3.7
4.0
e9/l
1.07
123
707
75
343
3.19
11.86
4.0
2.2
—
—
—
0
0
115
689
3.24
11.05
18.1
7.4
1.2
1.2
mmol/l
1.63
100
581
46
168
3.42
10.38
9.2
9.0
1.8
1.2
mmol/l
0.44
34
138
109
650
3.02
10.25
6.5
4.0
—
—
—
0
0
20
40
5.56
9.85
1.9
1.4
—
—
—
0
0
17
29
6.42
9.81
1.8
1.3
—
—
—
0
0
13
17
8.22
9.41
3.3
3.6
—
—
—
0
0
25
65
4.36
9.08
9.0
2.5
7.7
7.8
g/l
0.10
16
52
25
65
4.36
9.08
9.0
2.5
—
—
—
0
0
25
65
4.36
9.08
9.0
2.5
3.6
3.8
g/l
0.29
13
47
23
59
4.37
8.48
9.0
2.6
0.6
0.9
g/l
0.21
18
53
69
356
2.62
8.08
4.7
3.1
7726.5
7936.7
umol/l
0.01
64
299
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
46
4.54
7.50
2.3
3.8
0.3
0.3
u/ml
0.08
11
24
11
16
7.30
7.24
2.0
2.6
—
—
—
0
0
21
60
3.87
6.69
11.0
2.6
9.0
10.3
g/l
0.92
16
51
21
62
3.74
6.39
10.2
2.5
3.2
3.2
g/l
0.03
13
48
13
28
4.96
5.84
1.9
1.8
152.6
112.3
e6/l
0.10
13
19
47
240
2.34
5.31
2.4
1.9
—
—
—
0
0
14
35
4.28
5.29
1.7
1.8
—
—
—
0
0
27
106
2.85
5.20
8.3
8.6
25.3
24.8
mmol/l
0.31
27
106
83
537
2.10
5.18
4.2
3.4
—
—
—
0
0
83
546
2.05
4.87
4.2
3.8
30.7
49.8
ng/l
0.94
70
401
7
6
12.11
4.31
2.1
2.7
—
—
—
0
0
15
46
3.49
4.30
1.7
1.8
—
—
—
0
0
15
48
3.34
4.04
1.7
1.8
—
—
—
0
0
8
11
7.58
3.90
1.0
1.0
—
—
—
0
0
7
8
9.07
3.81
2.1
1.9
—
—
—
0
0
66
428
1.91
3.81
3.7
3.3
1.2
0.3
e6/l
0.39
51
313
14
46
3.23
3.62
3.1
3.4
8.3
8.7
kpa
0.34
14
39
29
141
2.28
3.59
5.2
3.8
—
—
—
0
0
13
41
3.36
3.58
2.6
2.5
27.6
23.7
mmol/l
1.85
13
32
24
109
2.41
3.46
2.7
1.6
—
—
—
0
0
55
345
1.89
3.46
2.2
2.0
2.6
3.0
mg/l
0.81
47
301
31
158
2.19
3.43
5.9
4.9
5.1
36.0
ug/l
0.60
25
131
11
32
3.61
3.40
1.5
1.7
—
—
—
0
0
153
1347
3.03
3.38
37.3
15.3
29.8
25.1
mg/l
1.08
140
1078
8
14
5.94
3.38
1.3
1.1
—
—
—
0
0
22
98
2.44
3.30
3.0
1.3
—
—
—
0
0
24
113
2.32
3.19
3.1
3.0
69.3
63.8
ml/min/173m2
0.29
12
52
14
50
2.97
3.17
2.6
1.9
—
—
—
0
0
7
12
6.04
3.05
2.1
3.8
18.6
21.7
u/ml
—
7
12
47
296
1.82
2.86
4.1
2.0
0.9
1.3
mg/l
1.49
38
235
13
48
2.86
2.79
2.2
1.8
—
—
—
0
0
23
114
2.18
2.72
13.3
5.2
1.2
1.2
mmol/l
0.96
23
105
10
32
3.26
2.69
1.9
1.4
—
—
—
0
0
10
32
3.26
2.69
1.9
1.4
—
—
—
0
0
10
33
3.16
2.57
1.2
1.3
—
—
—
0
0
132
1131
1.86
2.54
40.6
18.9
14.2
13.7
%
3.17
127
1116
9
27
3.47
2.43
1.7
1.7
—
—
—
0
0
24
129
2.01
2.32
1.8
2.6
0.2
0.2
g/l
0.28
24
119
23
122
2.03
2.30
3.7
4.2
4.1
4.7
kpa
1.64
23
115
17
80
2.26
2.28
2.4
1.5
—
—
—
0
0
26
145
1.94
2.27
6.1
4.8
6.0
5.7
kpa
0.45
26
138
9
29
3.22
2.26
1.7
1.9
—
—
—
0
0
143
1274
1.96
2.20
32.7
14.0
80.9
80.1
ml/min/173m2
0.13
126
1046
30
178
1.84
2.18
2.4
1.9
—
—
—
0
0
40
262
1.70
2.08
2.9
2.8
0.5
1.1
e6/l
1.32
24
149
7
20
3.61
2.08
1.3
1.6
—
—
—
0
0
29
173
1.82
2.07
2.4
1.8
—
—
—
0
0
34
213
1.75
2.07
4.0
2.4
2.2
2.3
g/l
0.50
34
193
38
249
1.68
1.97
4.1
3.0
3.6
1.9
e6/l
0.42
24
137
9
33
2.83
1.96
1.7
1.8
—
—
—
0
0
10
39
2.67
1.96
1.5
1.4
—
—
—
0
0
10
39
2.67
1.96
1.6
1.8
—
—
—
0
0
119
1020
1.61
1.95
6.8
4.3
18.7
12.4
mm/h
2.25
119
937
5
11
4.65
1.95
5.2
1.1
—
—
—
0
0
11
46
2.49
1.89
1.4
1.2
—
—
—
0
0
11
47
2.44
1.82
1.4
1.2
—
—
—
0
0
6
18
3.42
1.76
3.2
3.4
4.0
4.4
nmol/l
—
6
18
6
18
3.42
1.76
1.3
1.7
—
—
—
0
0
5
13
3.93
1.73
1.0
1.2
—
—
—
0
0
11
49
2.33
1.67
2.5
2.7
—
—
—
0
0
6
20
3.07
1.59
1.5
1.7
—
—
—
0
0
8
33
2.50
1.56
1.6
1.8
—
—
—
0
0
5
15
3.40
1.53
1.4
1.2
—
—
—
0
0
5
15
3.40
1.53
1.8
1.8
—
—
—
0
0
5
15
3.40
1.53
1.8
1.8
—
—
—
0
0
5
15
3.40
1.53
1.8
1.8
—
—
—
0
0
154
1441
2.13
1.53
42.2
17.9
85.7
78.9
umol/l
0.67
154
1441
14
73
2.00
1.49
1.3
1.4
—
—
—
0
0
38
267
1.55
1.49
1.7
1.7
1437.9
1188.3
nmol/l
0.56
30
200
9
39
2.38
1.45
1.6
2.1
—
—
—
0
0
5
16
3.19
1.45
2.0
1.9
—
—
—
0
0
69
551
1.44
1.44
1.9
2.0
86.5
93.8
pmol/l
0.50
43
276
14
74
1.98
1.44
1.2
1.2
1078.7
181.6
u/ml
0.44
14
66
14
75
1.95
1.39
2.1
3.8
26.1
2090.9
u/ml
0.55
14
61
22
138
1.69
1.35
4.2
2.2
378.8
374.7
nmol/l
0.05
22
127
0
40
0.00
1.34
0.0
3.0
—
89.1
—
0
21
5
18
2.83
1.29
1.8
1.8
—
—
—
0
0
14
80
1.82
1.17
5.4
3.0
0.3
0.1
e6/l
0.55
14
80
64
525
1.36
1.09
6.5
3.9
—
—
—
0
0
9
46
2.01
1.05
1.2
1.2
—
—
—
0
0
5
22
2.31
1.04
15.6
3.7
46.2
47.9
u/ml
—
5
22
9
48
1.92
1.02
1.7
1.9
—
—
—
0
0
46
364
1.37
0.97
6.2
4.2
0.0
0.0
estimate
0.00
20
126
118
1272
0.74
0.90
5.3
6.1
39.3
40.7
mmol/mol
0.97
110
1186
23
164
1.47
0.86
7.7
8.8
—
—
—
0
0
8
45
1.82
0.85
2.1
1.1
—
—
—
0
0
78
677
1.29
0.85
5.6
3.8
0.0
0.0
estimate
0.00
21
129
7
122
0.55
0.82
1.1
1.8
—
—
—
0
0
109
995
1.28
0.77
4.2
3.6
14.7
14.8
pmol/l
0.18
99
889
10
60
1.71
0.74
1.3
2.4
31.4
44.5
u/l
—
10
52
78
688
1.26
0.72
7.6
5.1
0.0
0.0
estimate
0.00
21
131
11
69
1.64
0.70
2.4
3.5
1.1
1.2
%
0.11
11
69
91
827
1.23
0.60
2.7
2.8
—
—
—
0
0
130
1359
0.79
0.53
4.2
5.1
2.6
2.7
mmol/l
1.09
118
1250
9
130
0.67
0.45
1.1
2.1
—
—
—
0
0
128
1222
1.22
0.43
34.8
16.3
36.1
40.1
%
4.27
88
869
76
696
1.17
0.42
5.7
3.8
0.0
0.0
estimate
0.00
21
121
5
33
1.53
0.41
1.6
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
7.7
—
0
9
0
16
0.00
0.41
0.0
1.5
—
—
—
0
0
34
292
1.21
0.39
1.6
1.8
442.1
468.0
pmol/l
0.28
26
252
5
36
1.40
0.38
1.4
1.4
—
—
—
0
0
6
42
1.44
0.36
1.5
1.7
—
—
—
0
0
6
88
0.67
0.34
1.3
1.7
—
—
—
0
0
127
1313
0.85
0.31
4.5
4.7
5.8
6.0
mmol/l
1.43
114
1201
15
122
1.25
0.28
2.0
2.2
5.7
8.0
ug/l
0.33
15
108
34
303
1.15
0.26
1.2
1.2
2.1
1.1
u/ml
0.44
13
81
129
1324
0.88
0.23
3.8
4.6
1.4
1.4
mmol/l
1.26
117
1215
130
1332
0.88
0.21
3.8
4.6
4.4
4.6
mmol/l
0.91
119
1232
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
58
546
1.10
0.19
4.2
5.1
2.7
2.8
ug/l
0.04
53
485
30
273
1.12
0.17
4.0
3.6
32.0
213.0
ng/l
2.02
22
216
127
1246
1.09
0.13
5.1
4.3
1.9
1.9
mu/l
0.00
117
1126
21
224
0.93
0.07
1.1
1.3
14.0
33.8
iu/ml
—
5
67
93
913
1.04
0.06
3.2
3.3
60.4
54.3
u/l
0.22
88
846
129
1278
1.04
0.04
3.5
4.1
1.2
1.3
mmol/l
0.53
120
1169
22
212
1.04
0.02
1.2
1.3
30.4
5.5
u/ml
—
5
85
12
113
1.07
0.02
1.2
2.8
155.8
191.6
ng/l
0.19
12
98
16
154
1.04
0.00
1.6
1.4
—
—
—
0
0
32
314
1.02
0.00
2.5
3.0
0.8
0.8
ug/l
0.01
22
218
14
144
0.97
0.00
2.1
2.3
43.0
34.9
u/l
—
9
120
43
434
0.99
0.00
3.9
4.3
21.4
21.6
%
0.02
19
225
23
227
1.02
0.00
1.3
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
55.7
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
7
71
0.99
0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
7.7
—
0
6
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
13.4
—
0
8
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
0.3
—
0
5
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_BONE_CARTILAGE_NAS – Malignant neoplasm of bone and articular cartilage of other and unspecified sites
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).